HLA-C and acute myeloid leukemia: Patients with the KIR2DL1/HLA-C*04 interaction showed the most reduced 5y-EFS rates also in B-ALL (77.3% vs. 93.8%, p = 0.036), T-ALL (75.0% vs. 91.7%, n.s.)and AML (50.0% vs. 87.5%, p = 0.05) patients.